e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

243.03 -2.84 (-1.16%)

Streaming Delayed Price Updated: 12:42 PM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Where Jazz Pharmaceuticals Stands With Analysts ↗

July 11, 2023

Via Benzinga

Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group ↗

July 10, 2023

Is the battle for medical marijuana legalization in North Carolina over for this year? Some groups say yes, some say know, here is what happened.

Via Benzinga

4 Unequaled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

July 08, 2023

Bargains are hiding in plain sight with the Nasdaq Composite still well below its November 2021 record-closing high.

Via The Motley Fool

Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful' ↗

June 23, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive day

Via Benzinga

10 Cannabis Stocks That Could Go Sky High In 2023 ↗

June 18, 2023

With cannabis legalization gaining momentum, investing in cannabis presents a lucrative opportunity. Investors may want to explore cannabis stocks to enhance their portfolios. Here are the top 10...

Via Talk Markets

Is Axsome Therapeutics Stock a Screaming Buy? ↗

June 15, 2023

The biotech could be staring down an enormous commercial opportunity.

Via The Motley Fool

Expert Ratings for Jazz Pharmaceuticals ↗

June 05, 2023

Via Benzinga

Where Jazz Pharmaceuticals Stands With Analysts ↗

May 15, 2023

Via Benzinga

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

Stocks That Hit 52-Week Lows On Tuesday ↗

June 13, 2023

On Tuesday, 32 companies reached new 52-week lows.

Via Benzinga

3 Cheap Growth Stocks That Are Too Good to Pass Up ↗

June 05, 2023

These top bargain growth stocks are all priced under $10 a share and offer real upside potential for investors.

Via InvestorPlace

Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

May 31, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END

Via FinancialNewsMedia

Recap: Jazz Pharmaceuticals Q1 Earnings ↗

May 10, 2023

Via Benzinga

Why Avadel Pharma Shares Are Gaining Today ↗

May 01, 2023

Via Benzinga

FDA Presents Potential Framework For CBD, From Edibles To Delta-8, Reaffirms Congress Is In Charge ↗

May 30, 2023

The U.S. Food and Drug Administration has not given up on regulating CBD and hemp-derived products in a way that would be safe for consumers and producers.

Via Benzinga

Ford To Rally Around 33%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

May 30, 2023

Keybanc boosted the price target for Broadcom Inc. (NASDAQ: AVGO) from $720 to $820. Keybanc analyst John Vinh maintained the stock with an Overweight rating. Broadcom shares rose 11.5% to close at...

Via Benzinga

Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity ↗

May 25, 2023

Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical...

Via Benzinga

World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients ↗

May 25, 2023

Can a cannabis-based medicine help treat aggressive brain tumors? Scientists in the UK are getting closer to answering that question. Ongoing lab research is about to become real-world as the project...

Via Benzinga

Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income? ↗

May 11, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2023, revealing revenue of $892.8 million, an increase of 10% compared to $813.7 million in Q1 2022.

Via Benzinga

Axsome's New Drug Is Scoring a Win. Is the Stock a Buy? ↗

May 09, 2023

The biotech's share price more than doubled during last year's bear market.

Via The Motley Fool

GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation ↗

May 09, 2023

Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope...

Via Talk Markets

Pressure BioScience's Pressure-Based Tech Is Ready To Spur Innovation And Growth In A Life Sciences Sector In Flux ↗

May 09, 2023

Often considered recession-proof, the life sciences sector faced a surprising amount of uncertainty over the past few years with up to 80% of companies saying they’ve been negatively impacted by the...

Via Benzinga

Why Shares of Avadel Soared This Week ↗

May 05, 2023

The company got its first FDA approval.

Via The Motley Fool

If You Invested $5,000 in Axsome Therapeutics 5 Years Ago, Here's How Much You Would Have Now ↗

April 25, 2023

Axsome's new products have blockbuster potential.

Via The Motley Fool

The Top Healthcare Stocks to Buy With $100 ↗

April 18, 2023

A small investment now may bring big results over time.

Via The Motley Fool

The Global Cannabis Pharmaceuticals Market Size Is Expected To Surpass $125 Billion by 2028

April 11, 2023

EQNX::TICKER_START (OTCQX:TCNNF),(OTCQX:CURLF),(NASDAQ:TLRY),(NASDAQ:JAZZ) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Cannabis

2 Top Biotech Stocks to Buy in April ↗

April 04, 2023

Right now you can pick up these stocks on the dip.

Via The Motley Fool

The 3 Best Growth Stocks to Buy in the Biotech Sector ↗

March 29, 2023

These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors.

Via InvestorPlace

Is Big Pharma Coming For Your Cannabis Business? ↗

March 27, 2023

Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies...

Via Benzinga

My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years ↗

March 21, 2023

The cannabis sector has been disappointing in recent years, but this company stands out.

Via The Motley Fool

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy